| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8790202 | Urologic Oncology: Seminars and Original Investigations | 2018 | 8 Pages |
Abstract
The role of LND for Gleason 7 prostate adenocarcinoma is not yet standardized, as indicated by the variability of LND dissection rates. Receipt of LND did not improve CSM, and in G43 patients, it predicted higher CSM. As the effect of LND on CSM is uncertain, further evaluation of oncologic benefit in this patient population is warranted.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Thenappan M.D., Hanan M.D., Zachary M.D., Rashid K. M.D., Robert J. M.D., M.P.H., F.R.C.S.C., Neil E. M.D., M.P.H., F.R.C.S.C., Girish S. M.D., Ph.D., F.R.C.S.C.,